Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | BCL2 | P10415 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorcyclizine SCHEMBL13724147 | 1.00 | KCNH2 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Chlorcyclizine SCHEMBL4383 | 1.00 | KCNH2 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Chlorcyclizine SCHEMBL16769331 | 1.00 | KCNH2 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Chlorcyclizine SCHEMBL321657 | 0.98 | CYP2D6 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Homochlorcyclizine SCHEMBL30402 | 0.94 | DRD3 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL2056217 | 0.93 | CHRM2 (0.86) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Homochlorcyclizine SCHEMBL1977999 | 0.92 | SMN1; SMN2 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Homochlorcyclizine SCHEMBL122573 | 0.92 | SMN1; SMN2 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| SCHEMBL7668121 | 0.91 | CHRM2 (0.83) | KCNH2CHRM2ADRA2ADRD3CHRM1 | |
| Cyclizine SCHEMBL4690 | 0.89 | CYP2D6 (1.00) | KCNH2CHRM2ADRA2ADRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| CN-106029060-A | piperidine and piperidine derivatives and their use in the treatment of viral infections and cancer | 美国卫生和人力服务部 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8049011-B2 | Process for the preparation of levocetirizine and intermediates thereof | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2011-11-01 | — | — | US | disclosed |
| US-20100105908-A1 | Process For The Preparation Of Levocetirizine And Intermediates Thereof | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | KCNH2 1569/4885CHRM2 1157/4885ADRA2A 1044/4885 |
| US-20100105908-A1 | Process For The Preparation Of Levocetirizine And Intermediates Thereof | CYP17A1, CYP51A1, NR5A1 | KCNH2 4211/4885CHRM2 744/4885ADRA2A 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.